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Abstract
Plasmodium falciparum causes most of the one million annual deaths from malaria. Drug resistance is widespread and novel
agents against new targets are needed to support combination-therapy approaches promoted by the World Health
Organization. Plasmodium species are purine auxotrophs. Blocking purine nucleoside phosphorylase (PNP) kills cultured
parasites by purine starvation. DADMe-Immucillin-G (BCX4945) is a transition state analogue of human and Plasmodium
PNPs, binding with picomolar affinity. Here, we test BCX4945 in Aotus primates, an animal model for Plasmodium falciparum
infections. Oral administration of BCX4945 for seven days results in parasite clearance and recrudescence in otherwise lethal
infections of P. falciparum in Aotus monkeys. The molecular action of BCX4945 is demonstrated in crystal structures of
human and P. falciparum PNPs. Metabolite analysis demonstrates that PNP blockade inhibits purine salvage and polyamine
synthesis in the parasites. The efficacy, oral availability, chemical stability, unique mechanism of action and low toxicity of
BCX4945 demonstrate potential for combination therapies with this novel antimalarial agent.
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Introduction
Plasmodium parasites are purine auxotrophs and require
preformed purine bases for synthesis of nucleotides, cofactors,
and nucleic acids [1]. Purine salvage in P. falciparum uses
hypoxanthine formed in erythrocytes or in parasites by the
sequential actions of adenosine deaminase (hADA, PfADA) and/
or purine nucleoside phosphorylase (hPNP, PfPNP) [2] (Figure 1).
Hypoxanthine, inosine and adenosine are transported from
erythrocytes into parasites by the equilibrative nucleoside
transporter (PfNT1) [3,4]. In erythrocytes, hypoxanthine and
ATP are in dynamic metabolic exchange via ADP, AMP, IMP,
inosine and adenosine. Hypoxanthine in the parasite is converted
to IMP by hypoxanthine-guanine-xanthine phosphoribosyl-trans-
ferase (PfHGXPRT) to provide inosine monophosphate (IMP), a
precursor for all required purines. Host and parasite PNPs are
essential for the formation of hypoxanthine, making PNPs a target
for the purine salvage pathway.
The polyamine biosynthetic pathway in P. falciparum depends on
PfADA and PfPNP to recycle 59-methylthioadenosine (MTA), a
product of polyamine synthesis (Figure 1). Its removal is necessary
for the cell to perform polyamine metabolism, since MTA is a
strong inhibitor of spermine synthase, spermidine synthase and of
ornithine decarboxylase [5,6,7]. Primates encode a specific MTA
phosphorylase for this purpose, but this activity is not found in P.
falciparum. Instead, the PfADA deaminates MTA to 59-methylthioi-
nosine (MTI), a metabolite not found in mammals [2] (Figure 1).
PfPNP converts MTI to hypoxanthine for subsequent conversion
to IMP. Blocking PfPNP therefore has the potential to block
purine salvage by preventing hypoxanthine formation and to
disrupt MTA recycling in the parasite, and thereby interfere with
polyamine metabolism. Polyamines neutralize charge on nucleic
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26916acids and are essential to rapidly proliferating cells like P.
falciparum, where they are a major metabolite [8]. Polyamine
synthetic pathways are important for parasites since mammalian
erythrocytes do not synthesize polyamines and only trace amounts
are found in serum [9].
Purine salvage in P. falciparum relies on hypoxanthine salvage
and can be disrupted with transition-state analogue inhibitors
effective against both human and Plasmodium PNPs (Figure 1).
Thus, inhibitors of human and Plasmodium PNPs are lethal for P.
falciparum cultured in vitro [10,11]. Although PNP is present both in
parasites and human erythrocytes, genetic evidence suggests that
PfPNP is critical for in vitro growth. P. falciparum genetically
disrupted in PNP have increased purine requirements and are
unable to thrive in vitro at physiological concentrations of
Figure 1. Purine and polyamine metabolisms in P. falciparum-infected human erythrocytes. Purine pathway: AMP, adenosine 59-
monophosphate; ADP, adenosine 59-diphosphate; ATP, adenosine 59-triphosphate; IMP, inosine 59-monophosphate; XMP, xanthosine 59-
monophosphate; GMP, guanosine 59-monophosphate; MTA, methylthioadenosine; MTI, methylthioinosine; AdS, adenylosuccinate; hADA, human
adenosine deaminase; hPNP, human purine nucleoside phosphorylase; hHGPRT, human hypoxanthine-guanine phosphoribosyl transferase; hAK,
human adenosine kinase; hAMPDA, human adenosine 59-monophosphate deaminase; hAPRT, human adenine phosphoribosyl transferase; PfADA,
P. falciparum adenosine deaminase; PfPNP, P. falciparum purine nucleoside phosphorylase; PfHGXPRT, P. falciparum hypoxanthine-guanine-
xanthine phosphoribosyl transferase; PfAMPDA, P. falciparum adenosine 59-monophosphate deaminase; PfIMPDH, P. falciparum inosine 59-
monophosphate dehydrogenase; PfGMPs, P. falciparum guanosine 59-monophosphate synthase; PfAdSS, adenylosuccinate synthase; PfAdSL,
adenylosuccinate lyase. Polyamine pathway: AdoMet, S-adenosylmethionine; AdoHC, S-adenosylhomocysteine; HC, homocysteine; Met,
methionine; dcAdoMet, decarboxylated S-adenosylmethionine; PfSpdSyn, P. falciparum spermidine synthase; PfODCAdoMetDC, P. falciparum
ornithine decarboxylase/S-adenosylmethionine decarboxylase; PfMetTfase, P. falciparum methyltransferase(s); PfAHC, P. falciparum S-adenosyl
homocysteinase; PfMetSyn, P. falciparum methionine synthase; PfAdoMetSyn, P. falciparum S-adenosylmethionine synthase. The metabolically
favored direction is indicated with bold arrows on reversible steps. The metabolic step inhibited by BCX4945 is indicated in red. Nucleoside/
nucleobase transporters are indicated on each membrane: human erythrocyte nucleoside transporter (brown), P. falciparum NT1 transporter (blue)
and yet-to-be characterized adenosine 59-monophosphate transporter (purple).
doi:10.1371/journal.pone.0026916.g001
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genetically disrupted in PNP are attenuated when infecting mice
[13].
P. falciparum is the most lethal of malaria parasites in humans
and it has narrow host specificity. Aotus monkeys provide a non-
human primate model for testing the efficacy of PNP transition-
state analogues against this parasite. Here, we report that
inhibition of PNP by orally administrated 49-deaza-19-aza-29-
deoxy-19-(9-methylene)-Immucillin-G (here named BCX4945),
clears the blood of P. falciparum in Aotus monkeys followed by
recrudescence when treatment is stopped. BCX4945 causes
depletion of hypoxanthine from Aotus blood, demonstrating
inhibition of both hPNP and PfPNP in vivo [11]. Moreover, we
apply metabolic tests to establish that PNP inhibition by BCX4945
blocks purine salvage, and demonstrate that polyamine synthesis is
also reduced in the human malaria parasite. We determine the
molecular mechanism of BCX4945 inhibition by providing the
crystal structures of BCX4945 with human and P. falciparum PNPs.
This is the first time that this class of compounds is proved to be
effective in a primate in vivo malaria model.
Results
PNP as an anti-malarial target
Purine salvage pathways have been targets for anti-malarials
since the discovery that Plasmodium parasites are purine auxotrophs
[14]. Adequate inhibition of PNP requires inhibitors with
extraordinary affinity as the enzyme is present at high levels in
the host erythrocytes and in P. falciparum [15]. Thus, in P. falciparum
in vitro cultures, it is reported that the half-maximum inhibitory
concentration (IC50) for PNP inhibitors increases with the
hematocrit [11]. Immucillins are powerful picomolar transition-
state analogue inhibitors of both human and Plasmodium PNPs
[16]. They are orally available and of low toxicity to animals and
humans [17]. We selected BCX4945 as an inhibitor for in vivo trials
because of its high affinity for both host and parasite PNPs (7 pM
and 890 pM Kd values, respectively) [18]. We assayed BCX4945
with different P. falciparum strains at human physiological
concentration of hypoxanthine (,10 mM) [19] to determine the
IC50 (Figure 2A). Parasitaemia was assessed by measuring
PicoGreen fluorescence from nucleic acids of the parasites [20].
BCX4945 inhibited P. falciparum growth in vitro and the IC50 values
were similar in a drug-sensitive strain 3D7 (164620 nM) [10] and
in a chloroquine/mefloquine-resistant strain Dd2 (130622 nM)
and a chloroquine/quinine resistant strain FVO (202627 nM).
These values were obtained at 1% hematocrit. At low concentra-
tions BCX4945 caused increased parasitaemia relative to controls.
Erythrocyte PNP is inhibited preferentially at low BCX4945 levels,
resulting in increased cellular inosine to cause enhanced parasite
growth [11].
Inhibition of both human and P. falciparum PNPs blocks inosine
conversion into hypoxanthine and induces purine starvation, thus
inhibiting parasite proliferation [2,11]. Metabolic studies using
[
3H]inosine in the presence BCX4945 showed complete inhibition
of the radiolabeled inosine incorporation into the purine pool in P.
falciparum-infected erythrocytes (Figure 2B). Radiolabeled inosine
accumulated in the culture media of treated parasites, since it is
exclusively metabolized by human and PfPNPs (Figure 2B, INO-S).
In contrast to the block in [
3H]inosine incorporation in the
presence BCX4945, [
3H]hypoxanthine incorporation continues at
reduced levels, except into inosine in the supernatant (Figure 2C,
INO-S). Hypoxanthine, but not inosine, can bypass PNP
inhibition (Figure S1). Supernatants analyzed from P. falciparum-
infected erythrocytes labeled with [
3H]hypoxanthine revealed that
hypoxanthine is converted to [
3H]IMP and to inosine by an IMP
phosphohydrolase (Figure 2C). Thus, when PNP is blocked, added
[
3H]hypoxanthine accumulates as [
3H]inosine in the supernatant.
Erythrocytes have active equilibrative nucleoside transporters [21]
and the efflux of labeled inosine reflects the inability of cells to
convert inosine to hypoxanthine when PNP is inhibited.
Metabolite levels of adenosine, MTA, inosine, MTI and
hypoxanthine were quantitated in P. falciparum-infected human
erythrocytes and uninfected-erythrocytes, with and without
BCX4945-treatment. The supernatants from each condition were
also analyzed. We used liquid chromatography-mass spectrometry
(LC-MS) with deuterated internal standards to measure absolute
metabolite concentrations. No hypoxanthine was found in
BCX4945-treated infected erythrocytes or the supernatant
(Table 1). However, inosine accumulated to 60 mM in the cellular
supernatant when PNPs were blocked (Table 1). In contrast,
inosine was not detected in normal infected erythrocytes, showing
the robust activity of PNPs (Table 1). MTI is a metabolite only of
the parasite and is a substrate for PfPNP. Hence, MTI
concentration increased in the supernatant of BCX4945-treated
Figure 2. BCX4945 inhibits PNP to block inosine salvage. (A) Chemical structure and effect of BCX4945 on in vitro growth of different P.
falciparum strains. Parasites were incubated in the presence of the indicated concentrations of BCX4945 for 72 h at 1% hematocrit, followed by DNA
quantitation. IC50 values were calculated from fits (Origin software) to the overall response curve. The graph is constructed by individual point
connections. (B, C) Counts per minute (cpm) levels of [
3H]inosine and [
3H]hypoxanthine metabolically incorporated into purine derivatives. P.
falciparum infected-red blood cells in schizont and trophozoite stages were metabolically labeled with [
3H]inosine or [
3H]hypoxanthine in the
absence or presence of 10 mM of BCX4945. Labeled inosine (INO-S) and hypoxanthine (HX-S) present in the supernatant. Means 6 s.d. from triplicates
are represented.
doi:10.1371/journal.pone.0026916.g002
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PfPNP (Table 1).
P. falciparum requires PNP to recycle MTI, a product of
polyamine metabolism in parasites but not found in human
metabolism. We explored the biochemical block by BCX4945 to
determine if it perturbed polyamine metabolism in parasites
(Figure 1). Putrescine, spermidine and spermine in infected-human
erythrocytes were significantly reduced by BCX4945 treatment
(Table 1). Thus, inhibition of PfPNP also inhibits polyamine
metabolism in the parasites. Polyamines are a major metabolite in
malaria parasites, estimated to be ,14% of the small molecule
metabolites [8]. However, strategies targeted specifically to
polyamines have not found success in antimalarial therapy,
supporting purine metabolism as the primary target of
BCX4945 [9,22].
Therapeutic efficacy of BCX4945 in P. falciparum infection
in vivo
Encouraged by its potency in inhibiting P. falciparum prolifer-
ation in vitro, we tested BCX4945 for efficacy in Aotus lemurinus
lemurinus monkeys infected with P. falciparum (FVO strain). In Aotus
primates (Owl monkeys) infection by P. falciparum FVO is
consistently lethal using the present protocol and without
antimalarial intervention [23]. BCX4945 orally administered
(50 mg kg
21) twice a day for seven days cleared P. falciparum
infections between the fourth and the seventh day of treatment
(Figure 3A). Monkeys remained parasite-negative for up to nine
days post-treatment (Table 2). All three BCX4945-treated
monkeys eventually recrudesced when treatment was terminated;
however, a lower rate of parasitic growth was observed (Table 2).
No signs of toxicity were observed during the study period (30 days
after the first dose). Transient decreases in hemoglobin and
hematocrit detected at day 12 post-infection, and increased
glutamate pyruvate transaminase activity were attributed to the
malaria infection (Table S1, tab PD-2).
The action of BCX4945 caused inhibition of PNP and
disruption of purine salvage in P. falciparum-infected Aotus. PNP
activity was assayed in infected-blood cell pellets. Blood samples
from an infected untreated monkey showed increased PNP activity
as the parasitaemia increased (Figure 3B) while treated animals
showed approximately 98% PNP inhibition during the treatment
period (Figure 3B). Eleven days after the last dose of BCX4945,
only ,25% of the PNP enzymatic activity was regained (Figure 3B,
day 18). Earlier studies in mice had demonstrated that picomolar
PNP inhibitors remain bound to PNP for the life-time of the
erythrocyte as a consequence of tight-binding to the enzyme.
Thus, the kinetics of PNP activity return in blood is equal to the
rate of hematopoiesis [24]. In Aotus infected with P. falciparum, the
rate of erythrocyte replacement increases as a consequence of the
anemia caused by the malaria infection (Table S1), as the normal
erythrocytes lifespan in monkeys is 86 to 105 days [25]. Thus, PNP
activity regain from BCX4945 treatment in Aotus blood was
increased by P. falciparum infection, interpreted as a consequence of
altered hematopoiesis rates (Figure S2).
Purines in P. falciparum-infected Aotus
Exogenous hypoxanthine provides a metabolic by-pass to PNP
inhibition (Figure 1 and S1). Thus, we characterized hypoxanthine
levels in blood cells and plasma from A. l. lemurinus monkeys before
and during P. falciparum infection (Table 3). In human volunteers,
plasma hypoxanthine is reported to be 2.7 mM( n=20) [26].
Serum hypoxanthine in Aotus trivirgatus monkeys is reported to be
in the range of 31 to 192 mM [27]. Our findings are similar in A. l.
lemurinus monkeys where hypoxanthine is the major purine base in
Table 1. Polyamine and purine levels in cultured P. falciparum infected-erythrocytes and human erythrocytes after 24 h treatment
with 5 mM BCX4945.
Infected-erythrocytes (nmoles/mg protein) Erythrocytes (nmoles/mg protein)
Metabolite Control BCX4945-treated Control BCX4945-treated
Cell pellet Putrescine 0.7060.05 0.260.1 (0.01) 0 0
Spermidine 3.960.3 1.160.3 (0.02) 0.06060.004 0.06060.003
Spermine 0.2560.02 0.0760.03 (0.01) 0.03560.002 0.03060.002
Adenosine 12661 0 645 62 2.6060.03 (0.2)
Inosine 24661 9 650 3 7 66 (0.04)
Hypoxanthine 3136121 0 (0.007) 0 0
MTA 0.760.2 0.660.1 0 0
MTI 0.760.3 0.660.1 0 0
BCX4945 02 0 66 (0.004) 0 36612 (0.07)
Infected- erythrocytes (mM) Erythrocytes (mM)
Metabolite Control BCX4945-treated Control BCX4945-treated
Supernatant Adenosine 1.560.4 0.460.2 (0.08) 0.360.1 0.660.2 (0.2)
Inosine 06 1 65 (0.0001) 0 863 (0.08)
Hypoxanthine 2167 0 (0.004) 0.7260.1 0 (0.04)
MTA 00 0 0
MTI 0.1060.04 0.360.1 (0.03) 0 0
BCX4945 05 60.6 (0.0002) 0 4.060.2 (0.01)
Data are mean 6 s.d. from two experiments, p values are in parentheses.
doi:10.1371/journal.pone.0026916.t001
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mean=40 mM; blood cells: 19 to 140 mM, mean=64 mM;
Table 3). After Aotus monkeys were infected with P. falciparum
both plasma and cellular hypoxanthine significantly dropped
(plasma: 0 to 40 mM, mean=6 mM; blood cells: 0 to 83 mM,
mean=21 mM; Table 3).
Inosine is also abundant in normal Aotus and was found mainly
in the blood cells (plasma: 0 to 18 mM, mean=2 mM; blood cells:
0.3 to 13 mM, mean=3 mM; Table 3). Similar to hypoxanthine,
inosine levels dropped during P. falciparum infection (plasma: 0 to
4 mM, mean=0.5 mM; blood cells: 0 to 7 mM, mean=1 mM;
Table 3). Treatment with BCX4945 to inhibit PNP activity caused
inosine concentration to increase above 50 mMi nAotus plasma
and blood cells while hypoxanthine concentration dropped below
0.3 mM (Figure 3C). Although BCX4945 treatment caused inosine
accumulation, inosine cannot be converted to hypoxanthine in the
presence of BCX4945. Adenosine is also a purine precursor for
malaria parasites since it is converted to inosine by PfADA. Both
plasma and blood cell adenosine levels were low (0.5 to 2 mM) and
did not vary significantly with BCX4945 treatment. However, in
untreated Aotus, adenosine concentration dropped as the infection
progressed (Figure S3).
A human physiological substrate for PNP is 29-deoxyguanosine
and as expected, BCX4945 treatment increased the levels of 29-
deoxyguanosine both in plasma and in blood cells (Figure S3).
Purines in Aotus blood returned to normal levels 18 days post-
BCX4945 treatment even though PNP activity in erythrocytes
remains 75% inhibited (Figure 3B, 3C, and Figure S3).
BCX4945 pharmacokinetics and pharmacodynamics
Pharmacokinetics of BCX4945 were determined in uninfected
and in infected Aotus treated orally (50 mg kg
21), or intravenously
(10 mg kg
21) once a day for three days. Oral bioavailability of
BCX4945 was 28% (F) and reached approximately 6 mMi n
plasma within 1 h of the first dose and up to 15 mM as the
maximum concentration (Cmax) independent of infection (Figure
S4). The Cmax value for BCX4945 was achieved earlier in infected-
monkeys (2 h versus 6 h in uninfected-monkeys). At 24 h following
the first dose, BCX4945 was found in plasma at ,1.2 mM in orally
treated uninfected-animals. However, the half-life (t K) in plasma
was similar in animals orally (1.2 h) and intravenously (1.3 h)
treated and these values were not affected by P. falciparum
infection. Infected Aotus treated with once a day BCX4945 oral
dosing (50 mg kg
21) for three days showed a 99% reduction of
parasitaemia that returned rapidly following completion of
treatment, as BCX4945 is cleared in 8 h from plasma (Figure
S4 and S5A). Metabolite profiles in these monkeys showed that
hypoxanthine decreased to near zero when BCX4945 is present
(Figure S5B). Hypoxanthine remained near zero in plasma
(0.360.2 mM) and BCX4945 persisted (0.660.2 mM) throughout
the treatment period when BCX4945 was given twice a day at
50 mg kg
21 per dose, explaining the enhanced antimalarial effect
(Figure S3).
Structural basis for BCX4945 inhibition of PNPs
Crystal structures of human and P. falciparum PNPs bound to
BCX4945 were determined to 2.3 and 2.0 A ˚ resolution,
respectively (Table S2). Other structures of human and malarial
PNPs have been reported, but these are the first with BCX4945
[28,29] (Figure S6 and S7). Human and malarial PNPs are
structurally diverse but both catalyze the phosphorolysis of purine
nucleosides using the same DN*AN (SN1) stepwise mechanism
[18]. Human and malarial PNPs have similar geometric
arrangement of the purine-, ribose- and phosphate-binding sites
[29] but use different amino acids within the catalytic sites and
exhibit distinct kinetic properties (Figure 4, Table S3) [29,30].
Figure 3. Oral administration of BCX4945 inhibits PNP and clears P. falciparum from infected Aotus monkeys. (A) Parasitaemia in
infected untreated monkey (IUM, n=1) or infected treated monkeys (ITM, n=3). The arrow indicates mefloquine treatment to cure the infected
untreated control monkey. Grey bar on the x-axis indicates days of treatment. (B) Blood cell PNP activity was assayed from untreated (n=1) and
treated monkeys (n=3, means 6 s.d.). Each sample was analyzed in triplicate. (C) Samples from blood cells and plasma were analyzed by UPLC-MS/
MS. The (24) time point indicates blood was taken before the monkey was infected. The (0) time point indicates that blood was drawn before the
treatment started. Day 1 reflects parasitaemia or metabolite levels 24 h after the first dose and the metabolic effect of two BCX4945 doses within
24 h (also for days 2 to 5). Days 12 and 18 are counted from the start of treatment.
doi:10.1371/journal.pone.0026916.g003
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a hydrophobic pocket with specific interactions to Asn243 and
Glu201 as hydrogen acceptors from the NH7 (2.8 A ˚), NH1 (2.8 A ˚)
and NH2 (3.0 A ˚) groups (Figure 4A). Asn243 also donates a
hydrogen bond to O6 of the deazaguanine group (3.1 A ˚). The
dihydroxypyrrolidine cation of BCX4945 serves as a transition
state ribocation mimic and is surrounded by hydrophobic residues
(Tyr88, Phe159, Phe200, Met219) with a H-bond between the 59-
hydroxyl mimic and His257 (2.8 A ˚) and with Phe159 contributed
from the adjacent subunit of the trimer (Figure 4A, Figure S6A).
The nucleophilic phosphate anion forms a 2.7-A ˚ ion pair with the
cationic nitrogen of the ribocation mimic and hydrogen bonds to
the 39-hydroxyl group, which is additionally hydrogen-bonded to
Tyr88 (2.6 A ˚) (Figure 4A). Phosphate bound to human PNP is
dianionic [31] and its binding site includes amide nitrogens (Ser33,
Ala116), the side chains of Ser33, Arg84, His86 and Ser220, and
the cation contact from BCX4945. The carbonyl of Ala116 and
the side chain of Tyr192 interact with phosphate through a
structural water molecule (Figure 4A). The close ion pair between
the tightly bound phosphate and BCX4945, in a hydrophobic
environment, is a major contributor to its picomolar binding
affinity.
The purine binding site of PfPNP is surrounded by peptide
bonds (Ser91, Cys92 and Gly93 of the b5 strand and Val181,
Glu182 and Met183 of the b10 strand) and hydrophobic residues
(Tyr160, Met183, Pro209 and Trp212). The hydrogen bond
between Asp206 and NH7 (2.8 A ˚) mimics the interaction
involving the N7-protonated guanine leaving group at the
transition state. A structural water molecule stabilized by Asp206
and Trp212 is in a hydrogen bond with O6 (2.7 A ˚) of BCX4945
(Figure 4B). The ribocation mimic of BCX4945 is surrounded by
His7, Val66, Tyr160, Met183, Glu184 and Asp206, with His7
contributed from the adjacent subunit of the hexamer (Figure 4B,
Figure S6B). The 39- and 59-hydroxyl groups of BCX4945 form
hydrogen bonds with side chains of Glu184 (2.6 A ˚) and His7
(2.6 A ˚). The side chains of Tyr160 (2.8 A ˚) and Asp206 (2.8 A ˚)
immobilize a water molecule in contact with the 59-hydroxyl
group (2.8 A ˚). Phosphate binding involves the amide nitrogens of
Gly23 and side chains of Arg27, Arg45, Arg88 and Ser91, with
Arg45 contributed from the adjacent subunit (Figure 4B). Similar
to human PNP, a 2.8-A ˚ ion pair between phosphate and the
ribocation mimic is a favorable energetic feature of BCX4945
binding. Phosphate also interacts with the ribocation mimic via the
39-hydroxyl of BCX4945 (Fig. 4B).
Discussion
BCX4945, a transition state analogue of both human and
malarial PNPs, cleared P. falciparum infection in Aotus non-human
primates, a close model of human malaria infection. Monkeys
cleared of blood parasites by oral BCX4945 treatment remained
negative for several days followed by recrudescence with a
decreased rate of parasitic growth. This pattern in the Aotus model
is termed ‘clearance and recrudescence’ (see materials and
methods) and is often seen with effective antimalarials (see below).
Parasite killing results from ‘‘purine starvation’’ since added
hypoxanthine rescues cultured parasites from PNP inhibitors.
Although metabolic studies also indicate inhibition of polyamine
synthesis, as expected from the dual function of PNP in P.
falciparum, polyamines are reduced, not depleted, indicating purine
starvation as the dominant mechanism of action.
Inhibition of PNP as an antimalarial approach differs from all
current therapies, suggesting utility in extending the current WHO
protocols for malaria treatment using combination therapy
approaches. The chemical class of PNP transition state analogues
that includes BCX4945 is reported to be orally available and to
exhibit low toxicity in humans [17,32,33]. BCX4945 showed a
moderate oral availability (F=28%) in Aotus monkeys. Our
metabolic and structural studies support BCX4945 action via its
tight binding to the PNP targets to induce purine-less death in P.
falciparum both in vitro and in vivo. PNP is abundant in mammalian
erythrocytes; and erythrocytes are constantly replaced. Therefore,
the purine levels in Aotus blood returned to normal after treatment
ceased, even when blood PNP remained partially inhibited.
Pharmacokinetics of BCX4945 indicated rapid clearance from
Aotus plasma (t K=1.2–1.3 h) and was similar in infected animals.
However, the Cmax value for BCX4945 was achieved earlier in
infected-monkeys (2 h versus 6 h in uninfected-monkeys).
BCX4945 absorption is reminiscent of quinine metabolism where
acute malaria influences its absorption [34]. A short half-life in
plasma is also observed in artemisinin derivatives (,3 h), which
are current front-line antimalarials [35]. Artemisinin derivatives
are not well suited for monotherapy as they also cause clearance
and recrudescence [36,37]. However, the WHO has initiated
artemisinin-based combination therapy with great success [35].
In our studies with BCX4945 given once a day (50 mg kg
21) for
three days, P. falciparum parasitaemia was reduced by .99%
(Figure S5A). However, with once-a-day dosing, BCX4945
concentration in plasma fell to zero between doses. When infected
Table 2. Parasitaemia values of infected-Aotus monkeys
orally treated with 50 mg kg
21 of BCX4945 twice a day for 7
days.
Day # Control (IUM) ITM 1 ITM 2 ITM 3
21 0.6 0.7 0.7 0.5
Days of
treatment
0 6.2 7.2 0.7 7.5
1 11.5 1 0.2 0.6
2 62 0.6 0.01 0.3
3 221 0.01 0 0.01
4 350* 0.01 0 0.01
5 91{ 0.01 0 0
6 12{ 000
Days Post-
treatment
1 0.9 0 0 0
2 0.01 0.01 0 0
3 0 0.7 0 0.01
4 0 2.2 0 0.01
5 0 46 0 0.3
6 0 44* 0.01 0.2
7 0 1.9 0.3 0.7
8 00 0 . 2 1
9 0 0 3 7.2
10 cured 0 3.5 17.8
11 cured 11.3 92*
12 7.8 23.4
13 10.8* 1.5
Parasites per ml610
3.
*One dose of mefloquine (40 mg kg
21);
{one dose of artesunic acid (33 mg kg
21). (IUM), Infected untreated monkey.
(ITM), Infected treated monkey.
doi:10.1371/journal.pone.0026916.t002
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21) for seven
days, this dosing schedule cleared parasitaemia to .99.99% of the
original infection but recrudescence occurred after a period of
days. Increasing the frequency of BCX4945 administration was
more effective since the concentration of BCX4945 remained over
500 nM in plasma at all times during the treatment period (Figure
S3). The presence of BCX4945 in plasma is critical for its efficacy.
Metabolic differences between humans and Aotus suggest PNP
inhibition as anti-malaria therapy may be more effective in
humans. Aotus blood contains hypoxanthine at concentrations an
order of magnitude greater than found in humans and
hypoxanthine is the limiting metabolite for purine salvage in the
parasite. This metabolic finding suggests that BCX4945 treatment
may be more effective to reduce blood hypoxanthine in humans
than in Aotus. Since the mechanism of action of BCX4945 differs
from all other antimalarials currently in human use, its potential
application in combination therapies, similar to the use of
artemisinin-derivatives, is attractive.
Our studies using Aotus-P. falciparum model indicate that similar
to artemisinin [35], the clearance and recrudescence pattern may
result from a combination of the short drug half-life in plasma and
the high levels of hypoxanthine found in Aotus monkeys. However,
further investigations are required to establish potential therapeu-
tic resistance.
This work reports a promising agent to block the purine salvage
and inhibit polyamine pathways in lethal infections of P. falciparum.
The oral availability, chemical stability, unique mechanism of
action and low toxicity to humans makes PNP transition state-
analogues novel candidates for the treatment of malaria in
combination therapies.
Materials and Methods
Ethics statement
Pharmacokinetic and efficacy of BCX4945 in Aotus monkeys
infected with P. falciparum were performed under the Institutional
Animal Care and Use Committee of the Albert Einstein College
of Medicine acting under NIH/OLWA guidelines, Protocol
Title: Efficacy and Pharmacokinetics of Immucillin in the Aotus
Plasmodium falciparum Model, Protocol No. 20080706, approval
date October 20, 2008. This Institutional Animal Welfare
Assurance (A3312-01) is fully accredited by the Association for
the Assessment and Accreditation of Laboratory Animal Care
(AAALAC), February 22, 1983. Animal research at the Gorgas
Research Institute was approved by the ICGES Institutional
Animal Care and Use Committee (IACUC) (CIUCAL) under
the accession number 2008/03, reviewed and approved on July
2, 2008. All protocols were approved under the International
Guiding Principles for Biomedical Research Involving Animals
developed by the Council for International Organizations of
Medical Sciences (CIOMS), and the laws of the Republic of
Panama. The Statement of Compliance at the Gorgas Research
Institute (Instituto Commemorativo Gorgas de Estudios de la
Salud), Panama, has been reviewed by the Department of
Health & Human Services, Public Health Service, National
Institutes of Health, where the statement of Compliance
(Assurance) with standards for Humane Care and Use of
Laboratory Animals was reviewed by the Office for Protection
from Research Risks (OPRR) and approved under approval
number #A5389-01, originally approved on March 9, 1999.
Animals used under these approvals are documented third-
generation laboratory-bred animals. They are housed under
conditions permitting social interactions, laboratory breeding
and family interactions. All infections and blood sample
collections were conducted under protocols that ameliorate
suffering in accordance with the recommendations of the
Weatherall report, ‘‘The use of non-human primates in
research’’. Transfer of blood samples from Panama to New
York was accomplished under permit numbers 2009-08-46
issued August 12, 2009 and 2010-11-080 issued November 22,
2010 by the Department of HHS, Center for Disease Control,
Atlanta in a ‘Permit to Import or Transfer Etiological Agents or
Table 3. Hypoxanthine and inosine levels in Aotus monkeys’ plasma and blood cells before and during P. falciparum infection*.
Hypoxanthine (mM) Inosine (mM)
Plasma Blood cells Plasma Blood cells
Monkey
# Before infection
During
infection Before infection
During
infection Before infection
During
infection Before infection
During
infection
1 76.3 40.7 140.8 83.0 0.0 0.0 13.1 7.3
2 15.9 2.1 49.8 45.5 0.0 0.0 5.0 0.0
3 0.0 0.0 20.6 21.1 0.0 0.0 1.2 0.0
4 13.3 0.0 93.8 0.0 0.0 0.0 1.4 0.0
5 163.5 0.0 86.3 0.0 0.0 0.0 0.3 0.0
6 52.3 0.0 105.5 25.1 0.0 0.0 4.3 0.0
7 13.1 0.0 38.9 40.8 0.0 0.0 0.9 0.0
8 59.0 0.0 63.7 6.5 0.0 0.0 1.1 0.0
9 28.2 0.0 47.0 0.2 0.0 0.0 3.4 0.0
10 0.0 0.0 53.3 5.9 0.0 0.0 2.6 3.3
11 63.8 20.1 93.4 33.5 18.5 4.2 4.7 1.3
12 40.4 7.1 61.6 16.3 5.6 0.8 2.3 0.9
13 23.7 7.7 21.5 10.5 1.7 1.6 0.5 0.0
14 16.4 4.8 19.2 11.2 1.3 0.7 0.3 0.5
*Samples were collected before monkeys were infected with P. falciparum and four days after infection started.
doi:10.1371/journal.pone.0026916.t003
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by the Commission on International Trade in Endangered
Species (CITES), Panama, permit number SEX/A-19-10.
Human erythrocytes were obtained from healthy donors under
the Albert Einstein College of Medicine Committee on Clinical
Investigations Protocol M-1063.
Inhibition tests
The effect of BCX4945 on parasite growth of 3D7, Dd2 and
FVO strains was measured in a 72 h growth assay in the presence
of drug as described [10]. Briefly, synchronous culture in the
schizont stage was cultured for 24 h in media containing 10 mMo f
hypoxanthine. Ring stage parasite cultures (200 ml per well, with
1% hematocrit and 1% parasitaemia) were then grown for 72 h in
the presence of increasing concentrations of the drug. After 72 h in
culture, parasite viability was determined by DNA quantitation
using PicoGreen (Invitrogen) as described by Quashie and
colleagues [20]. The half-maximum inhibitory concentration
(IC50) calculation was performed with Origin software (OriginLab)
using a nonlinear regression curve fitting. Half-maximum
inhibitory concentration (IC50) is the concentration of inhibitor
needed to kill 50% of parasites.
Figure 4. Stereo view crystal structure of BCX4945 and phosphate bound to hPNP and PfPNP. Crystal structures of hPNP-BCX4945-PO4
(A) and PfPNP-BCX4945-PO4 (B) were determined to 2.3 and 2.0 A ˚ resolution, respectively. BCX4945 (grey) active site residues (yellow), residues from
adjacent subunits (green) and phosphate (orange) are indicated. Hydrogen bonds are indicated as black dashed lines. The ion-pair interaction
between the ribocation mimic and phosphate is indicated as a magenta dashed line with the distances indicated.
doi:10.1371/journal.pone.0026916.g004
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Synchronized, schizont stage parasites were washed in purine-free
medium to remove excess hypoxanthine and inoculated into freshly
drawn erythrocytes that had been washed and resuspended in purine-
free medium. The schizont stage parasites were cultured in purine-
free medium for 24 h to further reduce hypoxanthine inside the cell.
The resulting ring-stage parasites (1% parasitaemia, 4% hematocrit)
were incubated with 30 mM of BCX4945 for 30 min at 37 uC. After
incubation, parasites without washing the excess of inhibitor were
diluted into 96-well microtiter plates to a final BCX4945 concentra-
tion of 15 mM, 2% hematocrit, 1% parasitaemia, increasing
hypoxanthine or inosine concentrations up to 200 mMa n dc u l t u r e d
for 72 h. Parasite viability was determined by DNA quantitation as
described by Quashie and colleagues [20]. For each condition, two
independent experiments were carried out in triplicate.
Metabolic labeling and HPLC analysis
Infected-erythrocytes in trophozoite and schizont stages treated
with 10 mM BCX4945 or untreated were metabolically labeled
with 1 mM of [2,8-
3H]inosine (50 Ci/mmol, Moravek) or
[2,8-
3H]hypoxanthine (30 Ci/mmol, Moravek) at 37 uC for 1 h.
Samples were extracted with perchloric acid (PCA), neutralized
and analyzed by HPLC as described [10].
Polyamine quantification
Polyamines from 0.5 M PCA extracts were analyzed as the
dansyl-derivatives by HPLC/fluorescence on a Waters Millenni-
um system [38]. Protein concentration was determined with a
bicinchoninic acid (BCA) protein assay kit according to the
manufacturer’s instructions (Pierce) using BSA as a standard. Data
from biological samples were normalized to the protein content.
Purine metabolites and BCX4945 quantitation
Samples from blood cells, plasma and media were extracted and
analyzed in duplicate. Samples were placed in 96 deep-well plates,
treated with 0.5 M HClO4 at 1:7 (v/v, sample/HClO4) and
immediately mixed with 7 pmol of each internal standard, [2,
8-
2H2]adenosine, [2, 8-
2H2]inosine, [2, 8-
2H2]hypoxanthine and
[methylene-
2H2]BCX4945 synthesized as described below. Samples
were incubated for 20 min at 4 uC and neutralized with 5 M
KOH at 10:1 (v/v, HClO4/KOH) for 20 min at 4 uC. Plates were
centrifuged (10 min at 4,000 rpm, 4uC) and supernatants were
filtered through a MultiScreenH Filter Plate with UltracelH-10
Membrane (Millipore). Metabolite and inhibitor levels were
quantified by UPLC/MS/MS using a Xevo TQ mass spectrom-
eter (Waters). The separation of adenosine, inosine, hypoxanthine,
29-deoxyguanosine, MTA, MTI and BCX4945 was achieved with
an Acquity HSS T3 column (2.16100 mm, 1.8 mm, Waters) at 60
uC. The eluent system was composed of 5 mM ammonium
formate in water (A) and 5 mM ammonium formate in methanol
(B) with a gradient of 98% eluent A to 30% eluent B from 0.1 to
1 min, 70% eluent A to 80% eluent B from 1 to 1.5 min and back
to 98% eluent A from 1.5 to 2 min at a flow rate of 0.6 ml min
21.
Quantitative determination was performed in ESI positive-ion
mode using multiple-reaction monitoring (MRM) mode. The ion
transitions, cone voltage and collision energy used for ESI-MS/
MS analysis are presented in Table S4. The ESI capillary voltage
was 0.3 kV, source temperature was set at 150 uC and desolvation
temperature at 450 uC. Data acquisition and analysis were carried
out by MassLynx V4.1 and QuanLynx software (Waters). The
concentration of the metabolites was calculated by interpolation of
the observed analyte/internal standard peak-area ratio with the
corresponding calibration curve.
Pharmacokinetic and efficacy studies
Laboratory bred Aotus lemurinus lemurinus monkeys (0.75–0.89 kg)
were maintained as described [39]. Individuals received orally
50 mg kg
21 of BCX4945 in 10% sucrose by gastric intubation or
intravenously 10 mg kg
21 in phosphate buffered saline solution
(pH 7.4), once a day for three days. Blood samples were collected
before the treatment started (t=0), 0.05 h, 0.5 h, 1 h, 2 h, 6 h,
24 h, 48 h, and 6, 12 and 18 days after the first dose from each
monkey and processed as described below. Pharmacokinetic
parameters were calculated using PKSolver [40]. For efficacy
studies, Aotus monkeys were inoculated intravenously with 5610
6
parasites of the FVO strain of P. falciparum in an approved
treatment protocol. Four days after the onset of patency (parasite
counts ,5.0610
3/ml blood), monkeys received orally 50 mg kg
21
of BCX4945 in 10% sucrose, once a day for three days or twice a
day for seven days. Parasitaemia was determined by Giemsa-
stained thick blood smears prepared daily from the marginal ear
vein [41]. Blood samples were collected from each monkey and
transferred to tubes containing lithium heparin, centrifuged and
both plasma and blood cells were frozen at 280 uC until analysis.
Animals received a physical examination and blood chemistry
profiles were monitored after treatment as described previously
[42]. Any monkey not responding appropriately to treatment was
cured of its infection with mefloquine (40 mg kg
21). Response to
treatment is categorized as clearance and cure, clearance and
recrudescence, or suppression without clearance. The day of
clearance is defined as the first of three consecutive days in which
the thick blood films are parasite negative. The day of
recrudescence is the first of three consecutive days of positive
thick blood films after a period of clearance. Suppression is defined
as a transient decrease in the parasite count post-treatment
without clearance.
Blood PNP activity
Blood cell pellets were diluted (1:1) in PBS containing 0.3%
Triton X-100. PNP activity was determined spectrophotometri-
cally by adding 1 ml of the cell lysate to 1 ml of the reaction buffer
containing 50 mM KH2PO4 (pH 7.5), 1 mM inosine and 20 mU
xanthine oxidase (Sigma). Reaction progress was monitored at
293 nm for 20 min at 25 uC. After the reaction was completed,
sample hemoglobin concentration was determined by measuring
absorption at 414 nm and PNP activity was normalized to
hemoglobin concentration.
Crystallography
Recombinant hPNP and PfPNP proteins were expressed and
purified as described before [29,43]. The hPNP protein was
prepared in 50 mM Tris-HCl buffer at pH 8.5 containing 1 mM
dithiothreitol (DTT). The final concentration for crystallization
was 12 mg ml
21 in the presence of 1 mM BCX4945 and 5 mM
potassium phosphate; crystals were grown by sitting-drop vapour
diffusion at room temperature using 25% PEG 3350, 100 mM
Tris-HCl (pH 8.5) and 200 mM ammonium sulfate as the
precipitant. The PfPNP protein was prepared in 50 mM HEPES
(pH 7.4), 1 mM DTT and 3 mM potassium phosphate. The final
concentration for crystallization was 10 mg ml
21 in the presence
of 0.7 mM BCX4945. The PfPNP-BCX4945 complex was
crystallized in 10% PEG3350 and 100 mM sodium formate using
sitting-drop vapour diffusion at room temperature. Crystals of
hPNP-BCX4945 were transferred into a fresh drop of the
crystallization solution supplemented with 20% glycerol and
flash-cooled in liquid nitrogen. Crystals of PfPNP-BCX4945 were
transferred to a reservoir solution supplemented with 20% 2-
methyl-2,4-pentanediol (MPD) prior to flash-cooling in liquid
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at Brookhaven National Laboratory. All data were processed with
the HKL2000 program suite and the data processing statistics are
presented in Table S2. The crystal structures of hPNP-BCX4945
and PfPNP-BCX4945 were determined by molecular replacement
in MOLREP using the published structures of hPNP (PDB
accession 3K8O) and PfPNP (PDB accession 1Q1G), respectively,
as search models [44]. The models without BCX4945 were first
rebuilt in COOT and refined in Refmac5 [45,46]. The BCX4945
molecule was added in the last stages of refinement using the
Fo2Fc map and refined in Refmac5 [46]. The refinement statistics
are summarized in Table S2. The BCX4945-omitted electron
density maps of the hPNP-BCX4945 and PfPNP-BCX4945
complexes are shown in Figure S7. Atomic coordinates and
structure factors for the crystal structures have been deposited with
the Protein Data Bank under accession codes 3PHB for human
PNP with bound BCX4945 and phosphate and 3PHC for PfPNP
with bound BCX4945 and phosphate.
Synthesis of deuterated internal standards
Preparation of [2,8-
2H2]hypoxanthine and [2,8-
2H2]-
adenosine. Deuterium was incorporated into the purine rings
of hypoxanthine and adenosine following slight modification of the
procedure of Sajiki et al [47]. Hypoxanthine or adenosine (1 mmol)
was dissolved in 10 ml of D2O (99.8% D) in a round-bottom flask
equipped with a side arm attached through a stopcock to a vacuum
source. After adding 10% Pd/C (10% w/w), a septum-topped
condenser was affixed and the reaction flask was equilibrated with
hydrogen gas by repeated evacuation and addition of hydrogen
from a needle-tipped balloon. The mixture was refluxed for 24 h,
and the Pd/C was filtered off by passage through a 0.45-mm syringe
filter. Rotary evaporation of the filtrate yielded .90% of a white
solid. ESI-MS analysis (Finnigan LCQ, positive mode) revealed the
following isotopic distribution: hypoxanthine, m/z 139 (
2H2-M+H
+,
95%), 138 (
2H1-M+H
+, 5%); adenosine, m/z 270 (
2H2-M+H
+,
95%), 269 (
2H1-M+H
+, 5%).
Preparation of [2,8-
2H2]inosine. [2,8-
2H2]Adenosine
(149 mg, 0.553 mmol) was dissolved in 10 ml distilled water by
warming briefly in a microwave oven. Upon cooling to room
temperature, 15 units of adenosine deaminase (Sigma, Type IX,
calf spleen) was added, and the reaction mixture was left for 12 h.
Formation of inosine was confirmed by UV-vis spectroscopy
(lmax=251 nm). Inosine was isolated by reversed-phase HPLC
using a Waters 600 system with a 486 detector (monitoring at
260 nm) and a Waters Xterra Prep C18 column (306250 mm).
Elution was achieved isocratically with 90% A (distilled
water):10% B (50% aqueous methanol) at 14 ml min
21, yielding
110 mg (81%) of inosine (tR=8 min) and ,1 mg of unreacted
adenosine (tR=15 min). ESI-MS analysis of inosine revealed m/z
271 (
2H2-M+H
+, 95%), 270 (
2H1-M+H
+, 5%).
Preparation of [methylene-
2H2]BCX4945. [methylene-
2H2]-
BCX4945 was prepared by Mannich reaction according to the
previously reported procedure [48] with slight modification. To a
solution of (3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidine hydro-
chloride [49] (15 mg, 0.1 mmol), sodium acetate (8.2 mg,
0.1 mmol), and [
2H2]formaldehyde (Cambridge Isotope Labo-
ratories, 16 mg of 20% w/w aqueous solution, 0.1 mmol) in 0.5 ml
H2O was added 9-deazaguanine (15 mg, 0.1 mmol), and the
mixture was heated to 95uC for 21 h. The title compound was
purified as the hydrochloride salt by preparative HPLC using
isocratic 90% A (50 mM ammonium formate, adjusted to pH 4.0
with formic acid):10% B (50% aqueous methanol) at 14 ml min
21,
yielding 20 mg (70%) of a yellowish glass. HPLC retention time
(tR=5 min) agreed with that of an unlabeled BCX4945 standard.
ESI-MS analysis revealed m/z 282 (
2H2-M+H
+, 100%).
Supporting Information
Figure S1 Hypoxanthine/inosine rescue assays. Inosine
and hypoxanthine supplementation and recovery of growth
analysis in P. falciparum cultures treated with 15 mM BCX4945.
Infected erythrocytes were cultured in the absence of exogenous
purines followed by incubation in the presence of the BCX4945
and the indicated concentrations of purine for 72 h, followed by
DNA quantitation. Percent parasite survival is (DNA synthesized
by treated cells/DNA synthesized by control cells)6100. Means 6
s.d. from 2 independent experiments are represented.
(TIF)
Figure S2 PNP activity in uninfected and infected
treated monkeys. Aotus were treated with BCX4945 once a
day for three days (50 mg kg
21). Blood PNP activity was assayed
from an uninfected treated monkey (UTM, n=1) and infected
treated monkeys (ITMs, n=3, means 6 s.d.). Each sample was
measured in triplicate. The PNP activity of infected-animals
recovered faster after treatment stopped due to increased
hematopoiesis in response to parasite-induced anemia. Similar
values of PNP activity and recovery of activity after treatment were
observed in all uninfected treated monkeys independent of the
number of doses and the route of administration (data not shown).
(TIF)
Figure S3 Purines and BCX4945 levels in plasma and
blood cells from P. falciparum infected-Aotus monkeys
untreated or orally treated with BCX4945 twice a day for
seven days. Samples from blood cells and plasma were extracted
and analyzed in duplicate by UPLC-MS/MS. The concentration
of the metabolites was calculated by interpolation of the observed
analyte/internal standard peak-area ratio with the corresponding
calibration curve. Time point (24) indicates blood was taken
before the monkey was infected. Time point (0) indicates that
blood was drawn before the treatment started. Day 1 reflects
metabolite and BCX4945 levels 24 h after the first dose and the
metabolic effect of two BCX4945 doses within 24 h (also for days
2 to 5). Days 12 and 18 are counted from the start of treatment.
Data are from infected untreated monkey (n=1) and infected
treated monkeys (n=3, means 6 s.d.).
(TIF)
Figure S4 Single dose oral and intravenous pharmaco-
kinetic analysis of BCX4945 in Aotus. Uninfected (A, B) and
P. falciparum-infected monkeys (C, D) were treated once orally
(50 mg kg
21, filled circles, n=3) or intravenously (IV,
10 mg kg
21, open squares, n=4). BCX4945 levels in plasma
and blood cells were measured by UPLC-MS/MS using
[methylene-
2H2]BCX4945 as an internal standard. Pharmacokinetic
parameters were calculated using PKSolver.
(TIF)
Figure S5 Three-day oral treatment of P. falciparum-
infected Aotus and PNP activity. (A) Parasitaemia in infected
untreated monkey (IUM, n=1) and infected treated monkeys
(ITM, n=3) with BCX4945. Grey bar on the x-axis indicates days
of treatment. Oral once-a-day dosing (50 mg kg
21) for three days
reduced parasitaemia by 99%. Parasite regrowth resumed after the
last dose due to rapid BCX4945 clearance from plasma (see Figure
S4). At day 8 post-infection, the control animal (IUM) was treated
with one dose of mefloquine. Other animals were treated with one
dose of mefloquine at day 10 (ITM1 and ITM2) and 12 (ITM3)
post-infection. (B) Hypoxanthine (white bars) and inosine (black
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monkeys treated with oral BCX4945 for three days. One
uninfected animal and three infected animals were treated (means
6 s.d. are represented). Plasmodium infection reduces purine levels
in plasma and the blood cells. Hypoxanthine (,30 mM)
reappeared in the blood of infected animals three days after the
treatment ended.
(TIF)
Figure S6 The crystal structure of hPNP and PfPNP
bound to BCX4945. Crystal structures of hPNP-BCX4945-PO4
(A) and PfPNP-BCX4945-PO4 (B) were determined to 2.3 and
2.0 A ˚ resolution, respectively. Human PNP is a homotrimer with
single-domain monomers of 10 b strands and 8 a helices.
Monomer cores consist of a mixed seven-stranded b sheet (b2,
b3, b4, b1, b5, b10 and b6) which is flanked by eight a-helices. b5
is extended and participates in an additional four-stranded b-sheet
(b5, b9, b8 and b7). PfPNP is a homohexamer where each
monomer contains 11 b-strands and 7 a-helices and is folded
similarly to hPNP monomers. Human and malarial PNP
monomers share structural similarity (Ca r.m.s.d. of 2.5 A ˚) despite
sharing only 14% sequence identity. The asymmetric unit of the
crystal structure of hPNP-BCX4945-PO4 contained two distinct
homotrimers while the asymmetric unit of crystal structure of
PfPNP-BCX4945-PO4 contained one homohexamer organized as
a trimer of dimers. Despite differences in quaternary structure, the
location of the active site within monomers is similar. Subunit
contacts are essential to the formation of active sites in both PNPs.
The active sites of hPNP are located at interacting subunits within
the trimer, whereas the active sites of PfPNP are face-to-face
located at dimer interfaces.
(TIF)
Figure S7 The BCX4945-omitted electron density maps
of hPNP and PfPNP bound to BCX4945. (A) hPNP-
BCX4945-PO4 and (B) PfPNP-BCX4945-PO4. BCX4945 (grey),
active site residues (yellow), residues from adjacent subunits (green)
andphosphate (orange)areindicated. The BCX4945-omitted mFo -
DFc electron density map (contour at the 3 s) is drawn ingreen. The
partial BCX4945-omitted 2mFo -D F c electron density map (contour
at the 1 s) is drawn in blue.
(TIF)
Table S1 Weights and complete blood chemistry profiles of Aotus
monkeys.
(XLS)
Table S2 Data collection and refinement statistics.
(DOC)
Table S3 Residues in the active sites of human and PfPNP.
(DOC)
Table S4 MRM acquisition settings for purines and BCX4945
quantitation.
(DOC)
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